

Elements for assistance to patients with hematological malignancies to propose care lines: a scoping review

Elementos para assistência a pacientes com neoplasias hematológicas para propor linhas de cuidado: scoping review Elementos de asistencia a pacientes con neoplasias hematológicas para proponer líneas de atención: revisión de alcance

Mayane Cleisla dos Santos Rocha^I ORCID: 0000-0003-0669-9791

> Valéria Dantas de Azevedo^I ORCID: 0000-0002-2584-5996

Maria de Fátima Lucena dos Santos^{II} ORCID: 0000-0003-4231-8204

Rodolfo Daniel de Almeida Soares¹ ORCID: 0000-0001-5531-964X

Viviane Euzébia Pereira Santos¹ ORCID: 0000-0001-8140-8320

Isabelle Campos de Azevedo¹ ORCID: 0000-0001-5322-7987

'Universidade Federal do Rio Grande do Norte. Natal, Rio Grande do Norte, Brazil. "Empresa Brazileira de Serviços Hospitalares. Natal, Rio Grande do Norte, Brazil.

How to cite this article:

Rocha MCS, Azevedo VD, Santos MFL, Soares RDA, Santos VEP, Azevedo IC. Elements for assistance to patients with hematological malignancies to propose care lines: a scoping review. Rev Bras Enferm. 2023;76(2):e20220152. https://doi.org/10.1590/0034-7167-2022-0152

Corresponding author:

Mayane Cleisla dos Santos Rocha E-mail: mayanecleisla@hotmail.com



EDITOR IN CHIEF: Álvaro Sousa ASSOCIATE EDITOR: Priscilla Valladares Broca

Submission: 03-10-2022 **Approval:** 10-02-2022

ABSTRACT

Objectives: to identify the elements for assistance to patients with hematological malignancies to propose a care line. **Methods:** this is a scoping review, anchored in the JBI theoretical framework, with searches carried out in April 2021, in eight electronic databases and 10 repositories of theses and dissertations. **Results:** the final sample consisted of 93 studies, and the main forms of assistance provided that can support a care line for this public were imaging tests, immunophenotyping, chemotherapy regimens, radiotherapy, infection management, assessment of nutritional status, maintenance of oral function, symptom management and screening for second malignancies. **Conclusions:** the elaboration of a care line for onco-hematologic patients is necessary, considering the complexity surrounding the diagnosis and treatment of hematologic malignancies, in addition to the difficulties that are imposed in relation to access and continuity of care in the network.

Descriptors: Comprehensive Health Care; Patients; Patient Care Planning; Hematologic Neoplasms; Neoplasms.

RESUMO

Objetivos: identificar os elementos para assistência a pacientes com neoplasias hematológicas para propor uma linha de cuidado. **Métodos:** trata-se de uma scoping review, ancorada no referencial teórico do JBI, com buscas realizadas em abril de 2021 em oito bases de dados eletrônicas e 10 repositórios de teses e dissertações. **Resultados:** a amostra final foi composta por 93 estudos, e as principais formas de assistências prestadas que podem embasar uma linha de cuidado para esse público foram exames de imagem, imunofenotipagem, regimes quimioterápicos, radioterapia, gestão de infecções, avaliação do estado nutricional, manutenção da função oral, gerenciamento de sintomas e rastreio para segundas neoplasias. **Conclusões:** a elaboração de uma linha de cuidados para pacientes onco-hematológicos se faz necessária, tendo em vista a complexidade que cerca o diagnóstico e tratamento das neoplasias hematológicas, além das dificuldades que se impõem em relação ao acesso e continuidade do cuidado em rede.

Descritores: Assistência Integral à Saúde; Pacientes; Planejamento de Assistência ao Paciente; Neoplasias Hematológicas; Neoplasias.

RESUMEN

Objetivos: identificar los elementos para la asistencia a pacientes con neoplasias hematológicas para proponer una línea de atención. **Métodos:** se trata de una revisión de alcance, anclada en el marco teórico del JBI, con búsquedas realizadas en abril de 2021 en ocho bases de datos electrónicas y 10 repositorios de tesis y disertaciones. **Resultados:** la muestra final estuvo compuesta por 93 estudios, y las principales formas de asistencia brindadas que pueden sustentar una línea de atención a este público fueron pruebas de imagen, inmunofenotipificación, regímenes de quimioterapia, radioterapia, manejo de infecciones evaluación del estado nutricional, mantenimiento de la función oral, manejo de síntomas y detección de segundas neoplasias malignas. **Conclusiones:** es necesario el desarrollo de una línea de atención al paciente oncohematológico, dada la complejidad que rodea al diagnóstico y tratamiento de las neoplasias hematológicas, además de las dificultades que se imponen en relación al acceso y continuidad de la atención en una red.

Descriptores: Atención Integral de Salud; Pacientes; Planificación de Atención al Paciente; Neoplasias Hematológicas; Neoplasias.

ONLINE VERSION ISSN: 1984-0446

INTRODUCTION

Care lines (CL) refer to proposals for articulating resources and health production practices, based on the most relevant epidemiological needs. This allows defining a care flow through which users must travel through Health Care Networks (RAS - Redes de Atencão à Saúde) in order to meet their health needs (1-2).

In view of this, RAS are an organizational model of the health care system, with different technological densities, which are articulated to promote continuous, comprehensive and quality health care. Therefore, they propose to break with the fragmentation of care, by the continuity of health care at all levels of the system, focusing on the management of chronic conditions, concomitantly with acute conditions⁽³⁻⁴⁾.

In this regard, the care network for chronic non-communicable diseases is one of the priority networks, with emphasis on the prevention and control of some health conditions⁽⁵⁾, as cancer, in order to reduce the incidence of some types of malignancies and improve the quality of life of users with this disease.

That said, we observed the importance of a CL to organize health care that meets individuals' needs in the context of oncohematological diseases, in order to enable the provision of care in a timely manner for promotion, prevention, protection, surveillance, diagnosis, treatment and hematological cancer rehabilitation⁽⁶⁾, since they are cancers with a significant incidence in the population⁽⁷⁾.

Hodgkin's Lymphoma (HL), Non-Hodgkin's Lymphoma (NHL) and Multiple Myeloma (MM) represented, respectively, about 1.4, 7.0 and 2.3 million lives affected by these types of hematological malignancies⁽⁸⁾. In addition to this, The incidence rate of Chronic Lymphocytic Leukemia (CLL) and Acute Myeloid Leukemia (AML) has increased considerably in most countries⁽⁹⁾ and the incidence of HL cases increased by 38.6% between 1990 and 2017⁽¹⁰⁾.

Such diseases require specialized attention, rapid diagnosis and effective treatment, given their rapid evolution, such as AML, which, although the prognosis has improved in recent decades, only one in four patients survives five years or more⁽¹¹⁾. In this context, there is a need to systematize the care provided to these patients.

Therefore, it is essential to sum up the elements for the care provided to patients with hematological malignancies to elaborate and propose a CL for such a specific audience, in order to support a safe, quality and assertive care. Moreover, this compilation of knowledge can support clinical decisions and conduct taken, as well as the performance of professionals and the follow-up of patients between health services, therefore, with triggering and improvement of clinical itinerary, in order to ensure the provision of care based on the best available evidence.

Given the above, this study sought to answer the following guiding question: what are the elements for assistance to patients with hematological malignancies that can support the proposition of a CL?

OBJECTIVES

To identify the elements for assistance to patients with hematological malignancies to propose a CL.

METHODS

Ethical aspects

As it was research that used public domain materials and did not involve human beings, it was not necessary to be appreciated by the Research Ethics Committee. However, it is important to highlight that the copyright was respected with correct citation and referencing.

Study design

This is a scoping review, based on the method proposed by the JBI Reviewer's Manual and conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR): Checklist recommendations⁽¹²⁻¹³⁾. The research protocol is registered in the Open Science Framework (https://doi.org/ 10.17605/OSF. IO/VCGPQ).

This type of review aims to investigate scientific evidence, identify and map existing gaps in a given area of study⁽¹⁴⁾. It was developed through five stages: I- definition of research question; II- search for relevant studies; III- selection of studies; IV- data extraction and analysis; V- gathering, synthesis and presentation of results⁽¹⁵⁾.

Methodological procedures

The first stage included the elaboration of the research question through the PCC strategy (P = Population: onco-hematologic patients; C = Concept: assistance; C = Context: CL).

To complete the second stage, the descriptors that encompassed the largest number of studies related to the research topic were identified, through consultation in the Medical Subject Headings (MeSH), for descriptors in English, and in the Health Science Descriptors (DeCS), for descriptors in Portuguese. This process, added to the employment of the Boolean operator AND, culminated in the development of the following search strategy (with its respective descriptors in Portuguese): (Patients AND Patient Care Planning AND Hematologic Neoplasms).

Initially, as a way to ensure that there are no studies with the same theme registered in the OSF or published, a broad search was carried out on the platform and in databases to identify protocols or reviews with similar themes. From this diagnosis, it was followed with the steps to consolidate the scoping review.

Study selection consisted in identifying texts in the databases and repositories of theses and dissertations by reading title and abstract, for screening the works according to eligibility criteria and reading full text for data extraction. The analyses were performed by peers of reviewers independently and, in case of disagreement, there was discussion for reaching consensus. In cases of doubts and disagreements, the opinion of a third reviewer specialized in the area of the object of study was requested.

For the step of separating, summarizing and reporting the essential elements found, a structured instrument specifically designed for this purpose was used. This tool allowed data synthesis, interpretation and basic numerical analysis of the extent, nature and distribution of studies selected to compose the final sample.

Data source

The searches were carried out in April 2021 in the following databases and repositories of theses and dissertations: U.S. National Library of Medicine (PubMed), Scopus, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science, Science Direct, PSYCHINFO, EMBASE, Latin American and Caribbean Literature in Health Sciences (LILACS), The National Library of Australia's Trobe (Trove), Academic Archive Online (DIVA), Electronic Theses Online Service (EThOS), The Education Resources Information Center (ERIC), Theses Canada, DART-Europe E-Theses Portal, National ETD Portal, Theses and Dissertations from Latin America, CAPES Theses and Dissertations Portal and Portuguese Open Access Scientific Repositories (RCAAP - Repositórios Científicos de Acesso Aberto de Portugal).

Data collection and organization

From the studies included in the final sample, the following variables were extracted: year of publication, country of study, language, methodological design, level of evidence, level of health care, type of hematological cancer, the area of health professionals and CL used for assistance to patients with hematological malignancies. The studies' level of evidence was classified according to JBI proposal (16), categorized from one (I) to five (V).

Data mapping occurred through the use of a structured instrument, proposed by JBI Reviewers⁽¹³⁾, which enabled the identification of essential information from the studies, which made it possible to synthesize and interpret data, in addition to generating the basic numerical analysis of the extent, nature and distribution of the studies incorporated in the review.

Data analysis

The collected data were organized in Microsoft Excel 2016° spreadsheets, analyzed using simple descriptive statistics and presented in graphs, figures, charts and/or tables, as appropriate, to compose the results of this study.

RESULTS

Searches in the databases resulted in a final sample consisting of 93 studies, based on the selection process described in Figure 1.

Study characterization included in the final sample is described in Chart 1, according to year of publication, country of study, study design, level of evidence, level of health care, type of hematological malignancy and synthesis of CL identified.

There are productions from 1978 to the present day, in which an increase in the last decade stands out, with emphasis on the year 2019 (17; 18.28%). The language of publications was English (93; 100%). Most publications are from the United States of America (USA) (30; 32.26%).

The most developed study design was systematic review (29; 31.18%) and cohort (25; 26.88%). Thus, the level of evidence that stood out was II (29; 31.18%). The assistance provided to people with hematological malignancies stands out due to the levels of health care of high complexity (65; 54.62%) and medium complexity (49;

41.18%). The types of hematological malignancies most addressed in the studies were leukemias (42; 37.5%) and lymphomas (21; 18.75%). Moreover, the most approached type of care was treatment (50; 52.63%), followed by diagnosis (15; 15.79%).




Figure 1 - Flowchart of the selection process, adapted according to PRISMA-ScR⁽¹²⁾, Natal, Rio Grande do Norte, Brazil, 2021

It is noteworthy that some studies portrayed more than one type of care, more than one type of hematological malignancy and the care is applied at different levels of health care, as shown in Chart 1, which justifies the amount of these variables exceeding the amount of the sample (93; 100%).

Article references in the sample of data selected in this research are found in a file attached to the OSF and can be consulted from the access to the platform, through the *link* available in the second paragraph of the method.

DISCUSSION

The epidemiological relevance of hematological cancer and the interest in improving care for patients affected by this disease are confirmed by the specific care needs, the quantitative of the final sample of this research, the growing number of scientific productions carried out in the last decade and the increase in rates incidence of this type of cancer^(8-10,17-18).

The most frequent place of studies was the USA and European countries; on the other hand, it is observed that the African continent had no representation, which is possible to correlate with the investment in the technological apparatus and development of scientific productions in these countries⁽¹⁹⁻²⁰⁾.

Similarly, this relationship may be associated with the magnitude of hematological cancer⁽²¹⁻²²⁾ in this group of countries, given that North America has the second highest incidence of NHL cases and Europe ranks third in terms of diagnosis of this disease⁽²³⁾. Moreover, CLL and AML were more commonly diagnosed in countries located in Europe and North America between 1997 and 2017⁽⁹⁾.

Chart 1 - Study characterization regarding year and country of research development and the elements for assistance to patients with hematological malignancies, Natal, Rio Grande do Norte, Brazil, 2021 (n=93)

Cod*/Year/Country	Elements for assistance to patients with hematological malignancies
A1 [†] /2012 / Multicenter	Diamonto
A2 [†] / 2017 / United States of America	 Diagnosis Imaging tests used in diffuse large B-cell lymphoma, such as computed tomography and positron emission tomography.
A3 [†] / 2016 / Italy	
A4 [†] / 2016 / Colombia	
A5 [†] / 2017 / United States of America	
A6 [†] / 2019 / Austria	
A7 [†] / 2018 / United States of America	Diagnosis Use of gene expression profiling to assess molecular profiling at the time of diagnosis and guide
A8 [†] / 2019 / Multicenter	therapeutic decisions, such as next-generation sequencing.
A9 [†] / 2020 / Denmark	
A10 [†] / 2016 / United States of America	
A11 [†] / 2017 / Brazil	Diagnosis Clinical techniques, biopsies, complete blood count and differential counts, immunology tests, flow cytometry, radiological tests and genetic technologies such as chromosome analysis and DNA sequencing [†] .
A12 [†] / 2018 / European countries	
	Diagnosis Triple assessment based on clinical examination, imaging and biopsy.
A13 [†] / 2021 / United Kingdom	Treatment Surgery is the recommended primary treatment. Mass-forming disease, lymph node involvement, or distant disease may require systemic treatment, with indication for chemotherapy, monoclonal antibody, and/or autologous stem cell transplantation. Radiotherapy should be considered when complete excision is not possible, if surgical margins are positive despite total capsulectomy, or when there is chest wall invasion.
A14 [†] / 2020 / South Korea	Diagnosis Use of artificial intelligence-based algorithm for screening patients with suspected hematologic malignancies using cell population data generated by routine complete blood count.
A15 ⁺ /2012/Germany	Diagnosis Investigation of central nervous system involvement in the diagnosis of acute myeloid leukemia is considered necessary in children.
	Diagnosis Additional tests in diagnosis are medical history, performance status, physical examination, syndromes, comorbidities, biochemistry, clotting tests, serum pregnancy test in women of childbearing potential, hepatitis A, B, C, blood group, chest, 12-lead, electrocardiography, echocardiography.
	Treatment Central nervous system treatment is administered to all pediatric patients, including those who have no detectable central nervous system involvement.
	Treatment Hematopoietic stem cell transplantation is used as post-remission consolidation therapy.
A16 [†] / 2016 / Multicenter	Treatment
A17 [†] / 2015 / Iran	There is continued indication for allogeneic stem cell transplantation for acute myeloid leukemia, myeloproliferative neoplasia and bone marrow failure, and indication of autologous transplantation ir myeloma.
A18 [†] / 2017 / United States of America	Treatment
A19 [†] / 2018 / Germany	 Allogeneic hematopoietic stem cell transplantation is a treatment option for patients with relapsed and refractory T-cell lymphoma. It should be considered early, in most cases after the first recurrence, since advanced disease and multiple previous therapies predict a higher risk of non-relapse-related mortality and higher recurrence rates.

Chart 1

Cod*/Year/Country	Elements for assistance to patients with hematological malignancies
A20 [†] / 2022 / England	
A21 [†] / 2019 / United States of America	
A22 [†] / 2019 / United States of America	
A23 [†] / 2011 / Italy	
A24 [†] / 2008 / Italy	
A25 [†] / 2007 / United States of America	
A26 [†] / 2013 / Austria	
A27 [†] / 2014 / Austria	Treatment
A28 [†] / 2016 / China	Patients under 60 years of age are usually treated with standard induction intensive polychemotherapy, followed by intensive consolidation therapy after remission is achieved. May be associated with
A29 [†] / 2016 / United States of America	hematopoietic stem cell transplantation.
A30 [†] / 2017 / South Korea	
A31 [†] /2018/Turkey	
A32 [†] / 2017 / South Korea	
A33 [†] / 2018 / Finland	
A34 [†] / 2019 / China	
A35 [†] / 1978 / United States of America	
A36 [†] / 2018 / United States of America	
A37 [†] / 2018 / France	Treatment Rescue chemotherapy in case of refractory hematologic malignancies.
A38 [†] / 2019 / United States of America	Treatment Pregnant women - fetal toxicity occurs from cytostatic therapy groups during the first trimester, while chemotherapy can be safely administered during the second and/or third trimester and the combination of daunorubicin and cytarabine is recommended for induction. All tyrosine kinase inhibitors are
A39 [†] / 2020 / European countries	
A40 [†] / 2020 / Italy	
A41 [†] / 2017 / Italy	teratogenic and are contraindicated during pregnancy.
A42 [†] / 2019 / Taiwan	Treatment Brentuximab vedotin, antibody-drug conjugate, is well tolerated and effective in the treatment of Asian patients with relapsed and refractory Hodgkin's lymphoma. It can strengthen disease control before transplantation and improve post-transplant outcomes, even among heavily pretreated patients.
A43 [†] / 2018 / China	
A44 [†] / 2004 / Australia	
A45 [†] / 2016 / Switzerland	Treatment
A46 [†] / 2017 / Italy	Use of single-mode radiotherapy only in early stages of HL and low-grade NHL. In advanced stage patients, cycles of chemotherapy followed by radiotherapy can be associated.
A47 [†] / 2020 / Italy	Radiation therapy appeared to improve local control, which suggests that it may be a better choice for therapy when trying to balance treatment efficacy and tolerability.
A48 [†] / 2020 / Italy	
A49 [†] / 2017 / United States of America	
A50 [†] / 2014 / Netherlands	Treatment Older adults - patients should be encouraged to make decisions based on accurate information about the risks and benefits of all available treatment options, including investigational clinical trial drugs.
A51 [†] /2017/China	Treatment Immunotherapy is a safe, viable and well-tolerated treatment for patients with multiple myeloma and may be a promising strategy for relapsed or refractory cases.
A52 ⁺ / 2015 / China	

Cod*/Year/Country	Elements for assistance to patients with hematological malignancies	
A53 [†] / 2019 / United States of America		
A54 [†] / 2013 / Iran	Treatment Immunotherapies are at an investigation stage, but present an attractive means to develop a multimoda therapy with the potential for improved therapeutic efficacy.	
A55 [†] / 2018 / United States of America		
A56 [†] / 2019 / Canada		
A57 [†] / 2020 / United States of America		
A58 [†] / 2021 / Ireland		
A59 [†] / 2019 / United States of America	Treatment Older adults - an individualized and personalized approach to administering intensive therapies to older adults with hematologic disorders, with the options of intensive induction chemotherapy, hypomelting agents, allogeneic and autologous hematopoietic cell transplantation.	
A60 [†] / 2013 / Italy		
A61 [†] / 2012 / France	Treatment	
A62 [†] / 2007 / Switzerland	Older adults - comprehensive geriatric assessment to determine eligibility for treatment, including functional status, comorbidities, cognition, psychological or mental health, social support, nutritional	
A63 $^{\scriptscriptstyle \dagger}$ / 2019 / United States of America	status, and polypharmacy.	
A64 [†] / 2014 / Multicenter	Support Dental - comprehensive dental and oral assessment to identify and eliminate possible sources of infection, pain and trauma, such as teeth compromised by caries, in addition to pain control, maintenance of oral function, management of oral complications resulting from treatment and conservation of quality of life.	
	Support Dental - guidance on brushing three times a day, using ultra-soft brushes, as well as care with brush hygiene and conservation, in addition to frequent rinsing, especially in situations where hygiene is hampered by oral mucositis.	
	Support Dental - use topical analgesics or anesthetics to relieve pain from oral mucositis.	
	Support Dental - management of oral complications of chemotherapy/stem cell transplantation, such as encouraging the patient to maintain oral intake while suffering from dysgeusia. Maintenance of oral function, such as moistening the mouth with sips and sprays of water or saliva substitutes and mechanical flavor stimulants (chewing gum, sweet and sour candies) and the use of spray or mouthwash	
A65 [†] / 1996 / United States of America	Support	
A66 [†] / 2015 / Brazil	 Dental - elimination of potential sources of oral trauma, such as ill-fitting dentures, orthodontic appliances, poor/rough restorations, traumatic dentition and dental calculus. 	
A67 ⁺ / 2013 / Japan	Support Dental - chemotherapy grading tool that induces myelosuppression, to facilitate communication between the medical and dental team and the treatment of odontogenic infection triggered by therapy.	
A68 [†] / 2003 / United States of America	Support Multidisciplinary - screening of symptoms and appropriate intervention, from the implementation of	
A69 [†] / 2020 / Germany	interviews, referrals, coordination and monitoring of nursing. Specialist assessments as part of the initial routine regarding the practice of social service and psychology.	
A70 [†] / 2019 / United States of America	Support Changes in policies for early admission to the Intensive Care Unit for the care of infections in patients with hematopoietic malignancies.	
A71 [†] / 2017 / Poland	Support Nutritional - act prophylactically, based on the assessment of nutritional status, with the aid of various methods (questionnaires to assess the risk of malnutrition, anthropometric measurements, biochemical tests, among others), and introduce nutrient supplementation by enteral nutrition, by providing oral nutritional supplements or parenteral nutrition, in cases of malnutrition and cachexia already installed.	
A72 [†] / 2016 / England	Support Use low-dose prophylactic platelet transfusions for thrombocytopenic patients due to myelosuppressive chemotherapy or stem cell transplantation.	

Cod*/Year/Country	Elements for assistance to patients with hematological malignancies
A73 [†] / 2015 / China	Support Protocol implementation to effectively reduce the door-to-antibiotic time to meet the international standard of care in patients with neutropenic sepsis.
$A74^{\dagger}$ / 2006 / South Korea	- Support Assessment and management of infections associated with neutropenia, with prophylaxis for bacterial and fungal infections due to patients' compromised immune status.
A75 [†] / 2012 / United States of America	
A76 [†] / 2018 / Italy	
A77 [†] / 2019 / United States of America	Support Implementation of yoga therapy protocol in cancer, including body awareness, breathing awareness, adaptive movement, and relaxing imaging practice.
A78 [†] / 2007 / United States of America	Palliative care
A79 [†] / 2018 / United States of America	Engage patients in early care planning, which includes the realization of a life will, prognostic discussic treatment options, and life support treatment preferences.
A80 [†] / 2020 / United States of America	
A81 [†] / 2015 / Finland	Palliative care
A82 [†] / 2017 / Spain	 Manage symptoms, emotional support, attention to psychosocial and spiritual needs, advanced care planning and care coordination.
A83 [†] / 2015 / United States of America	
A84 [†] / 2019 / Netherlands	
A85 [†] / 2012 / United States of America	Palliative care Timely insert eligible patients into care that promotes quality of life, according to individual preference
A86 [†] / 2020 / Germany	
A87 [†] / 2014 / Brazil	
A88 [†] / 2019 / United States of America	
A89† / 2019 / Saudi Arabia	Post-treatment Screen for secondary malignancies or recurrence of cancer, minimization of risk factors and exposures and early intervention, if detected.
	Post-treatment Assess the persistence of treatment-related toxicity and the risks of late effects.
	Post-treatment Provide counseling on reproduction and basal fertility assessment, on sperm bank and oocyte bank. In case of sexual dysfunction, perform sex hormone replacement and/or treatment of vaginal dryness.
	Post-treatment Screen for psychosocial issues such as depression, anxiety, post-traumatic stress disorder, metabolic syndromes such as diabetes, weight gain or loss, dyslipidemia.
	Post-treatment Generate incentive to preventive health, with the practice of healthy life habits, recommendations for regular physical activity, maintenance of optimal body mass index, vaccination, routine screening for fatigue, routine screening and pain assessment, and sleep hygiene education.
A90 [†] / 2019 / China	Post-treatment Monitor minimal residual disease, prevention and treatment of recurrence.
A91 [†] / 2000 / Australia	Post-treatment Engage patients in support services, such as educational programs, support and volunteers, to support the return to routine at home and provide support to families.
A92† / 2014 / Australia	Post-treatment Apply a research tool for unmet needs of survivors in five areas: financial concerns, emotional health, access and continuity of care, information and relationships.

Chart 1 (concluded)

Cod*/Year/Country	Elements for assistance to patients with hematological malignancies
A93 [†] / 2017 / United States of America	Post-treatment Propose care models: 1. Advisory Model The person responsible for care becomes the primary care health professional, who has advanced oncology practice (nurse, oncologist or primary care physician focused on cancer survival). A survival consultation is held with follow-up visits with the formation of survival care plans, summary of late effects, symptom assessment and quality of life. 2. Shared Service Model The performance of care is shared between the cancer specialist and the primary care physician. In this relationship, the oncologist provides all cancer-related care in the post-treatment phase, while the risk of disease recurrence is higher. During this period, primary care physicians manage non-cancer care, if applicable. When deemed appropriate, the oncologist releases the patient for primary care, including a written summary of treatment in the transition of care and a survival care plan to help formalize communication channels, delegate responsibilities and ensure adequate medical follow-up.

*Cod - Code; †A - article; ‡DNA - deoxyribonucleic acid.

Furthermore, the most discussed malignancies in the studies were leukemias and lymphomas, in line with the need to provide care to patients, given that these are the types of hematological cancer most distributed among the population^(7,9,20,24-26).

Regarding the level of health care, the findings of this study reveal that onco-hematological care is concentrated at medium and high complexity levels, since cancer is a type of disease that requires adequate equipment and human resources to provide specialized care⁽²⁷⁻²⁸⁾.

However, Primary Health Care (PHC) plays a fundamental role in health promotion, focusing on cancer protection factors, disease screening, early diagnosis, regulation of patients for other levels of care and training of teams, in addition to coordinating and maintaining the care of users with cancer⁽²⁹⁾.

However, it is observed that there are difficulties in providing care to cancer patients in PHC services, due to the need for qualification of professionals involved in the process of identifying signs and symptoms, referral to early diagnosis and treatment, users' unequal access to available services and delays in carrying out tests and returning for consultations⁽²⁹⁾. Thus, it is necessary to improve actions at this level of health care, to minimize the delay in diagnosis, in the provision of care and in the use of resources, in order to guarantee comprehensive care for patients with hematological malignancies.

In this regard, early diagnosis increases success in treatment and chances of cure. Nevertheless, in pediatric leukemia⁽³⁰⁻³¹⁾, where primary prevention is not possible, related to modifiable factors⁽³²⁾, often recommended to adults, such as smoking, alcoholism, sedentary lifestyle and other lifestyle habits, the importance of identifying the various technologies developed for the investigation of the disease is emphasized⁽³³⁾.

Another aspect of remarkable relevance is supportive care⁽³⁴⁾, since it minimizes complications⁽³⁵⁾, such as high risk of infections, cachexia, mucositis, depression, loss of social function and other side effects of treatment and impairment caused throughout cancer⁽³⁶⁻³⁹⁾. In addition, it enables the experience of the cancer coping process with better quality of life and better response to malignancy treatment⁽⁴⁰⁻⁴¹⁾.

From this perspective, it is still necessary to infer a greater focus of the studies in the curative process, to the detriment of the detection and care directed to post-treatment. With this, there

is a growing increase in cancer survivors, from the development and success of anticancer therapies⁽⁴²⁾.

However, the mortality rate for hematological malignancies is still high^(7,43-44). Thus, palliative care aims to improve care during the final life trajectory and should be integrated in a timely manner in standard oncological care. Nevertheless, the implementation of intensive care until the end of life and frequent hospital deaths^(22,45-46)is still observed.

This is associated with the complex nature of hematological malignancies and their treatment, delays in end-of-life discussions, lack of integration of palliative care services and barriers at home for the patient to experience the end of life at home⁽²²⁾.

On the other hand, increased survival has implied a new demand for post-treatment care that is not yet met by health services, as studies reveal a high prevalence of unmet needs in this population, such as concerns about changes in concentration and memory, fatigue, change in sexual activity, anxiety, depression, and change in body image^(42,47-48).

Thus, there is a need for changes in the care of patients with hematological cancer. The determination of a CL that systematizes the therapeutic itinerary of these patients can minimize the existing gaps in the RAS and promote a safe, quality and timely care delivery that can provide a longer survival time⁽⁴⁹⁾.

Study limitations

A limitation of this study is the difficulty in accessing articles that are unavailable in full because they do not meet this criterion, a fact that may have led to the loss of publications that could enrich the findings of this study.

Contributions to nursing and health

The present study brings relevant contributions to health, especially in the field of onco-hematology, by highlighting the particularities of the elements that can compose a CL to systematize the services and care provided to patients.

It is worth emphasizing the importance of the multidisciplinary team, especially nursing, within this context, as it is the most present professional category throughout the care process. and, thus, with greater opportunities to identify patients' health-disease needs, outline and make the best decisions and conducts for the implementation of CL, when considering the particularities of each case.

CONCLUSIONS

In view of the findings, this research achieved the proposed objective and presented the main elements that can support the proposition of a CL for assistance to onco-hematologic patients, when it summarized important aspects about diagnosis, treatment, supportive care, palliative care and post-treatment assistance.

Overall, these patients face several obstacles to achieving specialized care, given the complexity surrounding the diagnosis and treatment of hematological malignancies, as well as difficulties that are imposed in relation to access and continuity of care in the

network, which often implies an unfavorable outcome and death.

To this end, this issue needs to be addressed in new research, seeking to raise evidence to base the practice of health professionals and the dynamics of health services, based on the needs presented, associated with the updating and training of health professionals with new knowledge.

CONTRIBUITIONS

Azevedo IC contributed to the conception or design of the study/research. Rocha MCS and Azevedo VD contributed to the analysis and/or interpretation of data. Santos MFL, Soares RDA and Santos VEP contributed to the final review with critical and intellectual participation in the manuscript.

REFERENCES

- 1. Marques M, Barbiani R, Nora CRD, Cremonese L, Miguel TB, Ciconet RM, et al. Line of care for the attention to morbimortality from external causes in adolescents and young people. Rev Bras Enferm. 2022;75(suppl 2). https://doi.org/10.1590/0034-7167-2020-0428
- 2. Trindade LF, Kolankiewicz ACB, Bandeira LR, Rodrigues CD, Zeitoune RCG, Loro MM. Praxis of family health teams in the care of cancer patients. Acta Paul Enferm. 2021;34. https://doi.org/10.37689/acta-ape/2021AO03054
- 3. Damaceno AN, Lima MADS, Pucci VR, Weiller TH. Health care networks: a strategy for health systems integration. Rev Enferm UFSM. 2020;10(14):1-14. https://doi.org/10.5902/2179769236832
- 4. Landim ELAS, Guimarães MCL, Pereira APCM. Healthcare network: systemic integration from the perspective of macromanagement. Saúde Debate. 2019:43(suppl 5). https://doi.org/10.1590/0103-11042019S514
- 5. Figueiredo AEB, Ceccon RF, Figueiredo JHC. Chronic non-communicable diseases and their implications in the life of dependent elderly people. Ciênc Saúde Colet. 2021;26(01). https://doi.org/10.1590/1413-81232020261.33882020
- Galvão ND, Souza RAG, Souza BSN, Melanda FN, Andrade ACS, Sousa NFS, et al. Cancer surveillance in Mato Grosso, Brazil: methodological and operational aspects of a university extension/research project. Rev Bras Epidemiol. 2022;25(suppl 1). https://doi.org/10.1590/1980-549720220002.supl.1.1
- Silva FF, Latorre MRDO. Survival from acute lymphocytic leukemia in children in the city of São Paulo, Brazil. Cad Saúde Pública. 2020;36(3). https://doi.org/10.1590/0102-311X00008019
- 8. GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1859-922. https://doi.org/10.1016/S0140-6736(18)32203-7
- 9. Dong Y, Shi O, Zeng Q, Lu X, Wang W, Li Y, et al. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp Hematol Oncol. 2020;9:14. https://doi.org/10.1186/s40164-020-00170-6
- 10. Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, et al. Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study. J Hematol Oncol. 2019;12(1):107. https://doi.org/10.1186/s13045-019-0799-1
- Vosberg S, Greif PA. Clonal evolution of acute myeloid leukemia from diagnosis to relapse. Genes Chromosomes Cancer. 2019;58(12):839-49. https://doi.org/10.1002/gcc.22806
- 12. Aromataris E, Munn Z (Editors). JBI Reviewer's Manual [Internet]. JBI; 2020 [cited 2021 Apr 28]. Available from: https://reviewersmanual.joannabriggs.org/
- 13. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467-73. https://doi.org/10.7326/M18-0850
- Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19-32. https://doi. org/10.1080/1364557032000119616
- 15. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097
- 16. The Joanna Briggs Institute Levels of Evidence and Grades of Recommendation Working Party. Supporting Document for the Joanna Briggs Institute Levels of Evidence and Grades of Recommendation [Internet]. The Joanna Briggs Institute. 2014 [cited 2021 Oct 10]. Available from: https://jbi.global/sites/default/files/2019-05/JBI%20Levels%20of%20Evidence%20Supporting%20Documents-v2.pdf
- 17. Syed-Abdul S, Firdani RP, Chung HJ, Uddin M, Hur M, Park JH, et al. Artificial intelligence based models for screening of hematologic malignancies using cell population data. Scientific Rep. 2020;10:4583. https://doi.org/10.1038/s41598-020-61247-0

- 18. Osterman CK, Triglianos T, Winzelberg GS, Nichols AD, Rodriguez-O'Donnell D, Bigelow SM, et al. Risk stratification and outreach to hematology/oncology patients during the COVID-19 pandemic. Support Care Cancer. 2021;29(3):1161-64. https://doi.org/10.1007/s00520-020-05744-y
- 19. Okoroiwu HU, López-Muñoz F, Povedano-Montero FJ. Bibliometric analysis of global sickle cell disease research from 1997 to 2017. Hematol, Transfus Cell Ther. 2022;44(2):186-96. https://doi.org/10.1016/j.htct.2020.09.156
- 20. Hofsefh LJ. Getting rigorous with scientific rigor. Carcinogenesis. 2018;39(1):21-5. https://doi.org/10.1093/carcin/bgx085
- 21. Mascaro JS, Waller AV, Wright L, Leonard T, Haack C, Waller EK. Individualized, single session yoga therapy to reduce physical and emotional symptoms in hospitalized hematological cancer patients. Integr Cancer Ther. 2019;18. https://doi.org/10.1177/1534735419861692
- 22. Verhoef MJ, Nijs EJM, Ootjers CS, Fiocco M, Fogteloo AJ, Heringhaus C, et al. End-of-life trajectories of patients with hematological malignancies and patients with advanced solid tumors visiting the emergency department: the need for a proactive integrated care approach. Am J Hosp Palliat Care. 2029;37(9):692-700. https://doi.org/10.1177/1049909119896533
- 23. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660
- 24. Lomonaco LA, Koifman RJ, Freire C. Clinical epidemiological profile and survival of hospital cases of acute leukemia in a reference hospital in Rio Branco: Acre, 2007-2014. Cad Saúde Colet. 2021;29(3). https://doi.org/10.1590/1414-462X202129030550
- 25. Leisch M, Jansko B, Zaborsky N, Greil R, Pleyer L. Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation? Cancers (Basel). 2019;11(2). https://doi.org/10.3390/cancers11020252
- 26. Damlaj M, Fakih RE, Hashmi SK. Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care. Blood Rev. 2019;33:63-73. https://doi.org/10.1016/j.blre.2018.07.003
- 27. Lopes-Júnior LC, Lima RAG. Cuidado ao câncer e a prática interdisciplinar. Cad Saúde Pública. 2019;35(1):1-3. https://doi. org/10.1590/0102-311X00193218
- 28. Jaggi LMA, Canabarro ST, Rabin EG, Caregnato RCA. Strategic management promoting teaching and service integration: multidisciplinary residency deployment in Onco-Hematology. Interface. 2018;22(66):939-49. https://doi.org/10.1590/1807-57622016.0906
- 29. Lombardo MS, Popim RC. Access of the patient to the cancer network under the "Sixty-Day Law": Integrative Review. Rev Bras Enferm. 2020;73(5):1-9. https://doi.org/10.1590/0034-7167-2019-0406
- Bezerra WSP, Ferreira Júnior MA, Azevedo IC, Cardoso MP, Cardoso AlQ, Frota OP, et al. Clinical and epidemiological profile of children and adolescents submitted to the hematopoietic cell transplantation. Biosci J. 2019;35(5):1622-32. https://doi.org/10.14393/BJ-v35n5a2019-36227
- 31. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16):3187-205. https://doi.org/10.1182/blood-2012-03-362608.
- 32. Tüfekçi O, Koçak U, Kaya Z, Yenicesu I, Albayrak C, Albayrak D, et al. Juvenile myelomonocytic leukemia in turkey: a retrospective analysis of sixty-five patients. Turk J Haematol. 2018;35(1):27-34. https://doi.org/10.4274/tjh.2017.0021
- 33. Silva FF, Latorre MRDO. Survival from acute lymphocytic leukemia in children in the city of São Paulo, Brazil. Cad Saúde Pública. 2020;36(3):e00008019. https://doi.org/10.1590/0102-311X00008019
- 34. Resick JM, Sefcik C, Arnold RM, LeBlanc TW, Bakitas M, Rosenzweig MQ, et al. Primary palliative care for patients with advanced hematologic malignancies: a pilot trial of the SHARE intervention. J Palliat Med. 2020;24(6):820-29. https://doi.org/10.1089/jpm.2020.0407
- 35. Gurney M, O'Dwyer M. Realizing Innate Potential: CAR-NK Cell therapies for acute myeloid leukemia. Cancers (Basel). 2021;13(7):1568. https://doi.org/10.3390/cancers13071568
- 36. Goswami P, Oliva EN, Ionova T, Else R, Kell J, Fielding AK, et al. Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study. Therapeutic Ther Adv Hematol. 2020;11:1-14. https://doi.org/10.1177/2040620720955002
- 37. Azoulay E, Shimabukuro-Vornhagen A, Darmon M, von Bergwelt-Baildon M. Critical Care Management of Chimeric Antigen Receptor T Cell-related Toxicity. Be Aware and Prepared. Am J Respir Crit Care Med. 2019;200(1):20-23. https://doi.org/10.1164/rccm.201810-1945ED
- 38. Olin RL. Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care. Hematology Am Soc Hematol Educ Program. 2019;2019(1):63-70. https://doi.org/10.1182/hematology.2019001300
- 39. Pagano L, Busca A, Candoni A, Criscuolo M, Giovanni DPM, Fianchi L, et al. Risk of infection in elderly patients with AML and MDS treated with hypomethylating agents. Acta Biomed. 2018;89(suppl 11):5-39. https://doi.org/10.23750/abm.v89i11-S.7988
- 40. Silva DA. Cancer patients and spirituality: an integrative review. Rev Cuid. 2020;11(3):e1107. https://doi.org/10.15649/cuidarte.1107
- 41. Talati C, Frantz D, Lubas A, Salamanca C, Tobon K, Kubal T. How I treat newly diagnosed acute myeloid leukemia in an outpatient setting: a multidisciplinary team perspective. Future Oncol. 2020;16(7):281-91. https://doi.org/10.2217/fon-2019-0781
- 42. Shakeel S, Tung J, Rahal R, Finley C. Evaluation of factors associated with unmet needs in adult cancer survivors in Canada. JAMA Netw Open. 2020;3(3):e200506. https://doi.org/10.1001/jamanetworkopen.2020.0506
- 43. Mehlis K, Bierwirth E, Laryionava K, Mumm F, Heussner P, Winkler EC. Late decisions about treatment limitation in patients with cancer: empirical analysis of end-of-life practices in a haematology and oncology unit at a German university hospital. ESMO Open. 2020;5(5). https://doi.org/10.1136/esmoopen-2020-000950

- 44. Odejide OO, Uno H, Murillo A, Tulsky JA, Abel GA. Goals of care discussions for patients with blood cancers: association of person, place, and time with end-of-life care utilization. Cancer. 2020;126(3):515-22. https://doi.org/10.1002/cncr.32549
- 45. Freeman AT, Wood WA, Fox A, Hanson LC. Access to palliative care consultation and advance care planning for adults with high-risk leukemia. J Palliat Med. 2018;21(2):225-28. https://doi.org/10.1089/jpm.2017.0097
- 46. Porta-Sales J, Guerrero-Torrelles M, Moreno-Alonso D, Sarrà-Escarré J, Clapés-Puig V, Trelis-Navarro J, et al. Is early palliative care feasible in patients with multiple myeloma? J Pain Symptom Manage. 2017;54(5):692-700. https://doi.org/10.1016/j.jpainsymman.2017.04.012
- 47. Tsatsou I, Konstantinidis T, Kalemikerakis I, Adamakidou T, Vlachou E, Govina O. Unmet supportive care needs of patients with hematological malignancies: a systematic review. Asia Pac J Oncol Nurs. 2020;8(1):5-17. https://doi.org/10.4103/apjon.apjon_41_20
- 48. Herrmann A, Mansfield E, Tzelepis F, Lynagh M, Hall A. Use of the supportive care framework to explore haematological cancer survivors' unmet needs: a qualitative study. BMC Health Serv Res. 2020;20(1):1-13. https://doi.org/10.1186/s12913-020-05927-7
- 49. Delazeri S, Pasquini R, Castro AS, Pontes L, Gomes IM, Maluf EMPC, et al. Therapeutic itinerary of hematological patients: the importance of early diagnosis. Res, Soc Develop. 2022;11(4). https://doi.org/10.33448/rsd-v11i4.27670